145 related articles for article (PubMed ID: 27249708)
1. Considerations for Implementation of Cancer Molecular Diagnostics Into Clinical Care.
Hayes DF
Am Soc Clin Oncol Educ Book; 2016; 35():292-6. PubMed ID: 27249708
[TBL] [Abstract][Full Text] [Related]
2. Biomarker validation and testing.
Hayes DF
Mol Oncol; 2015 May; 9(5):960-6. PubMed ID: 25458054
[TBL] [Abstract][Full Text] [Related]
3. An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies.
Beaver JA; Tzou A; Blumenthal GM; McKee AE; Kim G; Pazdur R; Philip R
Clin Cancer Res; 2017 Mar; 23(6):1368-1372. PubMed ID: 27993967
[TBL] [Abstract][Full Text] [Related]
4. Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations.
Dobbin KK; Cesano A; Alvarez J; Hawtin R; Janetzki S; Kirsch I; Masucci GV; Robbins PB; Selvan SR; Streicher HZ; Zhang J; Butterfield LH; Thurin M
J Immunother Cancer; 2016; 4():77. PubMed ID: 27891226
[TBL] [Abstract][Full Text] [Related]
5. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
Dietel M; Jöhrens K; Laffert MV; Hummel M; Bläker H; Pfitzner BM; Lehmann A; Denkert C; Darb-Esfahani S; Lenze D; Heppner FL; Koch A; Sers C; Klauschen F; Anagnostopoulos I
Cancer Gene Ther; 2015 Sep; 22(9):417-30. PubMed ID: 26358176
[TBL] [Abstract][Full Text] [Related]
6. Genomic testing in oncology to improve clinical outcomes while optimizing utilization: the evolution of diagnostic testing.
Collymore DC; Kobilis SL; Lundquist TG; McGivney WT; Pezalla EJ; Poage W
Am J Manag Care; 2016 Feb; 22(2 Suppl):s20-5. PubMed ID: 26978033
[TBL] [Abstract][Full Text] [Related]
7. Cancer Proteomics and the Elusive Diagnostic Biomarkers.
Bradshaw RA; Hondermarck H; Rodriguez H
Proteomics; 2019 Nov; 19(21-22):e1800445. PubMed ID: 31172665
[TBL] [Abstract][Full Text] [Related]
8. Clinical proteomics in cancer: Where we are.
Panis C; Pizzatti L; Souza GF; Abdelhay E
Cancer Lett; 2016 Nov; 382(2):231-239. PubMed ID: 27561426
[TBL] [Abstract][Full Text] [Related]
9. A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.
Volckmar AL; Sültmann H; Riediger A; Fioretos T; Schirmacher P; Endris V; Stenzinger A; Dietz S
Genes Chromosomes Cancer; 2018 Mar; 57(3):123-139. PubMed ID: 29205637
[TBL] [Abstract][Full Text] [Related]
10. Proteogenomic studies on cancer drug resistance: towards biomarker discovery and target identification.
Fu S; Liu X; Luo M; Xie K; Nice EC; Zhang H; Huang C
Expert Rev Proteomics; 2017 Apr; 14(4):351-362. PubMed ID: 28276747
[TBL] [Abstract][Full Text] [Related]
11. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M
J Immunother Cancer; 2016; 4():76. PubMed ID: 27895917
[TBL] [Abstract][Full Text] [Related]
12. Standards in molecular diagnostics for the discovery and validation of clinically useful cancer biomarkers.
Vydelingum NA; Sorbara L; Wagner P; Srivastava S
Expert Rev Mol Diagn; 2013 Jun; 13(5):421-3. PubMed ID: 23782249
[TBL] [Abstract][Full Text] [Related]
13. Development and validation of risk models and molecular diagnostics to permit personalized management of cancer.
Pu X; Ye Y; Wu X
Cancer; 2014 Jan; 120(1):11-9. PubMed ID: 24114238
[TBL] [Abstract][Full Text] [Related]
14. Personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
[TBL] [Abstract][Full Text] [Related]
15. Implementation of a Precision Pathology Program Focused on Oncology-Based Prognostic and Predictive Outcomes.
Donovan MJ; Cordon-Cardo C
Mol Diagn Ther; 2017 Apr; 21(2):115-123. PubMed ID: 28000172
[TBL] [Abstract][Full Text] [Related]
16. Defining Clinical Utility of Tumor Biomarker Tests: A Clinician's Viewpoint.
Hayes DF
J Clin Oncol; 2021 Jan; 39(3):238-248. PubMed ID: 33326253
[TBL] [Abstract][Full Text] [Related]
17. Proteomic Approaches for Biomarker Panels in Cancer.
Tanase C; Albulescu R; Neagu M
J Immunoassay Immunochem; 2016; 37(1):1-15. PubMed ID: 26565430
[TBL] [Abstract][Full Text] [Related]
18. Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer.
Borrebaeck CA
Nat Rev Cancer; 2017 Mar; 17(3):199-204. PubMed ID: 28154374
[TBL] [Abstract][Full Text] [Related]
19. Marketing of personalized cancer care on the web: an analysis of Internet websites.
Gray SW; Cronin A; Bair E; Lindeman N; Viswanath V; Janeway KA
J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25745021
[TBL] [Abstract][Full Text] [Related]
20. Evidence of clinical utility: an unmet need in molecular diagnostics for patients with cancer.
Parkinson DR; McCormack RT; Keating SM; Gutman SI; Hamilton SR; Mansfield EA; Piper MA; Deverka P; Frueh FW; Jessup JM; McShane LM; Tunis SR; Sigman CC; Kelloff GJ
Clin Cancer Res; 2014 Mar; 20(6):1428-44. PubMed ID: 24634466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
